探索pentoxifylline作为Covid-19糖尿病患者德克萨米他的替代治疗方法:一个随机对照试验
Mohsen Gholinataj Jelodar1, Farahnaz Hoseinzadeh2, Samaneh Mirzaei3
1Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, School of Medicine, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran.
托西菲林 (PTXF) 通过减少炎症和血糖峰值,在治疗糖尿病COVID-19患者方面表现有前途. 这项研究表明,PTXF可能是一个比皮质类固醇更安全的替代品,用于在这个脆弱人群中管理COVID-19.
科学领域:
- 传染性疾病 传染性疾病
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 治疗COVID-19仍然是一个挑战,特别是对于糖尿病患者来说.
- 皮质类固醇是一种常见的治疗方法,引起了人们对高血糖和疗效的担忧.
- 需要替代抗炎药物来治疗糖尿病患者的COVID-19.
研究的目的:
- 为了评估pentoxifylline (PTXF) 与甲在糖尿病COVID-19患者中的有效性.
- 评估PTXF对炎症标志物和血糖水平的影响.
- 为了比较PTXF和德克萨米他在这个患者群体中的安全性和有效性.
主要方法:
- 在47名COVID-19糖尿病患者中进行了一项随机对照试验.
- 参与者除了接受标准护理外,还接受了PTXF或甲.
- 测量的主要结果包括炎症标志物 (白血球,中性粒细胞,淋巴细胞,IL-6,CRP),临床症状和血糖控制.
主要成果:
- 在第七天,PTXF组的白血球,中性粒细胞,淋巴细胞,IL-6和CRP水平显著降低,与德克萨梅他松组相比 (p <0.05).
- 在PTXF组中观察到血糖的明显较低升高.
- PTXF对炎症标志物和血糖控制产生了有利的影响.
结论:
- 托西菲林 (PTXF) 显示出作为糖尿病COVID-19患者有效治疗的潜力.
- PTXF可能有助于减少炎症和减轻与COVID-19相关的高血糖症.
- 进一步的研究支持PTXF作为这个人群的有前途的治疗选择.
更多相关视频
04:53Author Spotlight: Traditional Chinese Medicine for Sleep Disorders in Acute COPD — A Safe, Cost-Effective Approach
Published on: October 18, 2024
11:34A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes
Published on: April 11, 2025
相关概念视频
COPD: Management Using Bronchodilators and Corticosteroids
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Antiasthma Drugs: Methylxanthines
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
